Frank A. Ahmann
Chief Executive Officer at MateraCor, Inc.
Profile
Frank A.
Ahmann currently works at MateraCor, Inc., as President & Chief Executive Officer and Recardio, Inc., as Chief Operating Officer.
Mr. Ahmann also formerly worked at Allvivo, Inc., as President & Chief Executive Officer, LoneStar Heart, Inc., as President, Chief Operating Officer & Director, Edwards Lifesciences Corp., as Principal, Medpace Research, Inc., as Chief Operating Officer, CardioPolymers, Inc., as Chief Operating Officer, and Chimeric Therapies, Inc., as Principal.
Mr. Ahmann received his Masters Business Admin degree from The Trustees of Columbia University in The City of New York and undergraduate degree from The University of Texas at Austin.
Frank A. Ahmann active positions
| Companies | Position | Start |
|---|---|---|
Recardio, Inc.
 Recardio, Inc. Pharmaceuticals: MajorHealth Technology Recardio, Inc. operates as a clinical-stage life science company that focuses on therapies for cardiovascular, oncology, and infectious diseases. The company was founded by Roman Schenk and is headquartered in San Francisco, CA. | Chief Operating Officer | - |
MateraCor, Inc.
 MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Chief Executive Officer | - |
Former positions of Frank A. Ahmann
| Companies | Position | End |
|---|---|---|
| EDWARDS LIFESCIENCES CORPORATION | Corporate Officer/Principal | - |
| Chimeric Therapies, Inc. | Corporate Officer/Principal | - |
LoneStar Heart, Inc.
 LoneStar Heart, Inc. Miscellaneous Commercial ServicesCommercial Services LoneStar Heart, Inc. develops cardiac restorative therapies for patients with heart failure. The firm functions in collaboration with the Texas Heart Institute, the University of Texas Southwestern Medical Center and a global network of leading clinicians. Its flagship product is Algisyl-LVR, a medical device under clinical development intended to prevent or reverse the progression of advanced heart failure in patients who have an enlarged left ventricle. The company was founded in June 2010 by James T. Willerson, Eric N. Olson and Olav B. Bergheim and is headquartered in Laguna Hills, CA. | President | - |
Allvivo, Inc.
 Allvivo, Inc. Medical DistributorsDistribution Services Allvivo, Inc. develops & sells proprietary coated devices and novel biotechnology surfactants for the burgeoning proteomics, biologics and bioscience segments of the life sciences industry. The company was founded in December, 1999 and is headquartered in Lake Forest, CA. | President | - |
CardioPolymers, Inc.
 CardioPolymers, Inc. Pharmaceuticals: MajorHealth Technology CardioPolymers, Inc. provides novel biocompatible polymer implant therapies to treat cronic heart failures. The company was founded in 2003 and is headquartered in Laguna Hills, CA. | Chief Operating Officer | - |
Training of Frank A. Ahmann
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| The University of Texas at Austin | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| EDWARDS LIFESCIENCES CORPORATION | Health Technology |
| Private companies | 7 |
|---|---|
LoneStar Heart, Inc.
LoneStar Heart, Inc. Miscellaneous Commercial ServicesCommercial Services LoneStar Heart, Inc. develops cardiac restorative therapies for patients with heart failure. The firm functions in collaboration with the Texas Heart Institute, the University of Texas Southwestern Medical Center and a global network of leading clinicians. Its flagship product is Algisyl-LVR, a medical device under clinical development intended to prevent or reverse the progression of advanced heart failure in patients who have an enlarged left ventricle. The company was founded in June 2010 by James T. Willerson, Eric N. Olson and Olav B. Bergheim and is headquartered in Laguna Hills, CA. | Commercial Services |
Medpace Research, Inc.
 Medpace Research, Inc. Medical DistributorsDistribution Services Medpace Research, Inc. is a pharmaceutical company, which focuses on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. The company was founded by Billy G. Hudson, J. Wesley Fox Ahmann and Tryggvason Karl on May 25, 2004 and is headquartered in Cincinnati, OH. | Distribution Services |
Allvivo, Inc.
Allvivo, Inc. Medical DistributorsDistribution Services Allvivo, Inc. develops & sells proprietary coated devices and novel biotechnology surfactants for the burgeoning proteomics, biologics and bioscience segments of the life sciences industry. The company was founded in December, 1999 and is headquartered in Lake Forest, CA. | Distribution Services |
CardioPolymers, Inc.
CardioPolymers, Inc. Pharmaceuticals: MajorHealth Technology CardioPolymers, Inc. provides novel biocompatible polymer implant therapies to treat cronic heart failures. The company was founded in 2003 and is headquartered in Laguna Hills, CA. | Health Technology |
| Chimeric Therapies, Inc. | |
Recardio, Inc.
Recardio, Inc. Pharmaceuticals: MajorHealth Technology Recardio, Inc. operates as a clinical-stage life science company that focuses on therapies for cardiovascular, oncology, and infectious diseases. The company was founded by Roman Schenk and is headquartered in San Francisco, CA. | Health Technology |
MateraCor, Inc.
MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Health Technology |
- Stock Market
- Insiders
- Frank A. Ahmann
